• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

Donepezil and vitamin E in Alzheimer’s disease [Classics Series]

byMilana Bogorodskaya, MDandAndrew Cheung, MD MBA
March 12, 2014
in General Medicine Classics, Psychiatry Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. High-dose vitamin E supplementation does not slow down progression to Alzheimer’s disease 

2. Donepezil, a cholinesterase inhibitor, shows modest reductions in risk of progression to Alzheimer’s disease early in treatment

Original Date of Publication: June 9, 2005

Study Rundown: Around 80% of people who meet criteria for amnestic mild cognitive impairment go on to develop Alzheimer’s disease (AD) within the next six years. There has been a lot of research focused on ways of slowing down the process of cognitive impairment, including medications such as donezepil and supplements such as vitamin E. This study compared donepezil (a cholinesterase inhibitor), high-dose vitamin E supplementation, and placebo with regards to their effect at slowing down the progression to AD. The study found that while donepezil has some modest effects early on in treatment, vitamin E was not superior to placebo.

In summary, this study showed the modest effects of donezepil at reducing the progression to AD and that vitamin E was not effective in slowing down the progression of mild cognitive impairment. As shown in previous studies, this study also demonstrated that being a carrier of the APO-E e4 allele is the most significant risk factor in developing AD. Given the allele’s propensity for AD, it was included as a covariate when running statistical analysis of data. However, the paper did not show any data concerning the covariate.

Click to read the study in NEJM

RELATED REPORTS

Wellness Check: Sleep

The 2 Minute Medicine Podcast Episode 6

Lecanemab may slow cognitive decline in early Alzheimer’s disease

Study Author, Dr. Ronald C. Petersen MD PhD, talks to 2 Minute Medicine: Director of Alzheimer’s Disease Research Center, Mayo Clinic College of Medicine

“While the overall outcome of the study was negative, it raised the issue of using cholinesterase inhibitors in some subsets [of] patients with MCI highlighting the concept of biomarker stratification. That is, subjects who were carriers of the apolipoprotein E4 allele may have responded differently than the overall group of MCI subjects suggesting that certain subsets of subjects might be more appropriate for particular therapies.

Many studies are under way or being planned stratifying subjects with MCI according to their underlying biomarker profiles. This will likely enhance the probability of finding specific treatments for subsets of patients based on their biomarker profiles.”

In-Depth [randomized, controlled study]: This multicenter, randomized, double-blind, placebo-controlled trial took 769 subjects with mild cognitive impairment from across the United States and Canada and randomized them to receive either 2000 IU of vitamin E with a placebo, 10 mg of donezepil with a placebo, or placebos for both. All patients also took a daily multivitamin. Subjects were screened for mild cognitive impairment by several independent measures and were all between 55-90 years of age. The primary end point was time to the development of possible or probable Alzheimer’s disease, which was defined according to clinical criteria by multiple independent national neurological and Alzheimer’s disease organizations. Secondary outcomes included scores on a variety of assessment scales testing different aspects of cognition. Patients were followed for 3 years.

Results showed that there was no significant difference in progression to AD between the vitamin E group and the placebo group at any time during the 3 year trial (numerical data not provided in paper). Donezepil, on the other hand, did show modest reduction in risk of progression to AD compared to placebo, for the first 12 months of the trial (p=0.004 at 6 months and p=0.04 at 12 months). During years 2 and 3, the hazard ratios were lower, but still significant (p=0.03 for both years). However, by 36 months, the three groups did not differ significantly in the number of subjects who had progressed to AD (63 in donezepil group vs. 73 in placebo group, p=0.21). Secondary outcomes showed minor improvements in some of the assessments in the donezepil group compared to the placebo group but the differences were confined to the first 18 months of the study. The one marker that stood out was the APO-E e4 allele, with 76% of AD cases in the study occurring among carriers of the allele (p<0.001).

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: Alzheimer’s diseasedonepezilvitamin E
Previous Post

Preterm birth associated with elevated plasma insulin levels

Next Post

Fracture severity associated with treatment invasiveness for distal radius fractures

RelatedReports

Decline in adolescent sleep duration over past 20 years
Wellness

Wellness Check: Sleep

March 16, 2023
2MM Podcast

The 2 Minute Medicine Podcast Episode 6

February 9, 2023
Free alternatives comparable to Mini-Mental State Examination
Chronic Disease

Lecanemab may slow cognitive decline in early Alzheimer’s disease

January 10, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: The Genetics of Alzheimer’s Disease, the Silent Killer, a Holiday Blizzard and an HIV Vaccine on the Horizon

March 14, 2023
Next Post
Fracture severity associated with treatment invasiveness for distal radius fractures

Fracture severity associated with treatment invasiveness for distal radius fractures

Pregabalin improves symptoms of restless legs syndrome

Pregabalin improves symptoms of restless legs syndrome

Oxantel pamoate results in higher cure rates of Trichuris trichiura in children

Oxantel pamoate results in higher cure rates of Trichuris trichiura in children

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Abnormal menstruation may be associated with worse cardiometabolic outcomes later in life
  • Past infection with pre-omicron variants of COVID-19 protects against re-infection
  • No difference in complete expulsion of intrauterine device between early and standard interval postpartum placement
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options